Trials / Recruiting
RecruitingNCT07440225
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 960 (estimated)
- Sponsor
- EyeBiotech Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Conditions
- Macular Degeneration
- Age-Related Macular Degeneration
- Choroidal Neovascularization
- Wet Macular Degeneration
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiespectus | Administered by intravitreal (IVT) injection |
| DRUG | Aflibercept | Administered by intravitreal injection (IVT) |
Timeline
- Start date
- 2026-03-27
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
- First posted
- 2026-02-27
- Last updated
- 2026-04-15
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07440225. Inclusion in this directory is not an endorsement.